Nucleotide sequences for .alpha. chain variable regions in human lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

The present invention relates to new nucleotide sequences coding for variable regions of .alpha. chain T-cell receptors, corresponding peptided segments and the diagnostic and therapeutic uses.
It is known that the receptors recognizing antigens at the surface of mature T lymphocytes (hereafter designated T-cell receptors) possess a structure having a certain similarity with those of immunoglobulins. Therefore, they contain heterodimeric structures containing .alpha. and .beta. glycoprotein chains or .gamma. and .delta. glycoprotein chains (see Meuer et al. (1), Moingeon et al. (2), Brenner et al. (3), Bank et al. (4)).
The directory of T-cell receptors must be able to address the immense diversity of antigenic determinants. This is obtained by genetic recombination of different discontinuous segments of genes which code for the different structural regions of T-cell receptors. Thus, the genes contain V segments (variable segments), optionally D segments (diversity segments), J segments (junction segments) and C segments (constant segments). During the differentiation of T-cells, specific genes are created by recombination of V, D and J segments for the .beta. and .delta. loci and V and J segments for the .alpha. and .gamma. loci. These specific combinations as well as the pairing of two chains create the combinational diversity. This diversity is highly amplified by two supplementary mechanisms, namely the imprecise recombination of V-D-J or V-J segments and the addition of nucleotides corresponding to the N region (Davis et al. (5).
A certain number of genetic V segments are already known. These segments have been grouped into subfamilies as a function of the similarity of sequences. By definition, the segments which have more than 75% similarity in the nucleotide sequence have been considered as members of the same subfamily (Crews et al. (6)). The known V.alpha. genetic segments have also been classified into 22 subfamilies, 14 of which have only one member (see Concannon et al. (7), Kimura et al. (8), Wilson et al. (9)).
Moreover, about 60 J genetic segments have been described (9).
Furthermore, monoclonal antibodies directed against specific segments of the variable parts of T-cell receptors, in particular the .beta. or .delta. chains, were recently described in WO 90/06758. These monoclonal antibodies are useful not only as diagnostic tools but also as therapeutic tools, for example, vis-a-vis rheumatoid arthritis.
The use of synthetic peptides corresponding to the variable regions of the .alpha. or .beta. chains in the treatment of auto-immune diseases is also described (23 and 24).
It is also known that variations exist from one individual to another in the expression of different variable segments of the T-cell receptor in man (27 and 28).
The present inventions aims to enrich the directory of genetic segments coding for the variable regions of the chains of T-cell receptors by providing on the one hand new V.alpha. genetic segments belonging to new subfamilies or belonging to subfamilies of which at least one member is already known, and on the other hand, new J.alpha. genetic segments.
Therefore a subject of the present invention is nucleotide sequences coding for the variable regions of .alpha. chains of human T lymphocyte receptors, corresponding to cDNA's containing nucleotide sequences chosen from any one of the following:
a--V.alpha. segments corresponding to one of the sequences SEQ ID No. 1 to 11, and
b--J.alpha. segments corresponding to one of the sequences SEQ ID No. 12, 13 and 14 to 19, and the sequences which differ from them by one or more nucleotides.
More particularly a subject of the present invention is:
sequences coding for the variable regions of .alpha.-chains of human T lymphocyte receptors, corresponding to cDNAs containing nucleotide sequences chosen from any one of the V.alpha. segments corresponding to one of the sequences SEQ ID No. 1 to 10 and the sequences which differ from them by one or more nucleotides,
sequences coding for the variable regions of .alpha. chains of human T lymphocyte receptors, corresponding to cDNAs containing nucleotide sequences chosen from any one of the J.alpha. segments corresponding to one of the sequences SEQ ID No. 12, 13 and 14 to 19 and the sequences which differ from them by one or more nucleotides.
The expression "and sequences which differ from them by one or more nucleotides", encompasses alleles which differ by up to 8 nucleotides, but more often differ by 1 or 2 nucleotides or which can differ by the deletion or addition of one or two codons.
Also a more particular subject of the invention is:
nucleotide sequences coding for the variable regions of .alpha. chains of human T lymphocyte receptors, corresponding to cDNAs corresponding to all or part of the nucleotide sequences chosen from any one of the V.alpha. segments corresponding to one of the sequences SEQ ID No. 2 to 5, and the sequences which differ from them by one or two nucleotides,
nucleotide sequences coding for the variable regions of the .alpha. chains of human T lymphocyte receptors, corresponding to cDNAs corresponding to all or part of the nucleotide sequences chosen from any one of the V.alpha. segments corresponding to one of the sequences
1 to 200 of SEQ ID No. 1
1 to 467 of SEQ ID No. 6
1 to 77 of SEQ ID No. 7
1 to 151 of SEQ ID No. 8
291 to 386 of SEQ ID No. 9
1 to 260 of SEQ ID No. 10
and the sequences which differ from them by one or two nucleotides,
nucleotide sequences coding for the variable regions of the .delta. chains of human T lymphocyte receptors, corresponding to cDNAs corresponding to all or part of the nucleotide sequence corresponding to SEQ ID No. 11 and which contain the 108 nucleotide,
nucleotide sequences coding for the variable regions of the .alpha. chains of human T lymphocyte receptors, corresponding to cDNAs corresponding to all or part of the nucleotide sequences chosen from any one of the J.alpha. segments corresponding to one of the sequences SEQ ID No. 12, 13 and 14 to 19 and the sequences which differ from them by one or two nucleotides.
By the expression "nucleotide sequences corresponding to cDNAs corresponding to all or part of the nucleotide sequences" is also designated the complete sequences as well as fragments of these sequences including short fragments (oligonucleotides) which can be used as probes (generally containing at least 10 nucleotides) or as primers (generally containing at least 15 nucleotides). In a general fashion, the invention encompasses the group of new oligonucleotides which are fragments of V.alpha. and J.alpha. sequences according to the invention.
As to the sequences which differ by one or two nucleotides, they correspond to variations which are observed experimentally at the time of determination of the nucleotide sequence of several cDNAs.
Also a subject of the present invention is the peptides coded by the nucleotide sequences according to the invention as well as the alleles and the derivatives of the latter which have the same function.
Also a subject of the present invention is the peptides constituted by or composed of a peptide sequence coded by all or part of the sequence 108 to 364 of SEQ ID No. 11.
In a general fashion, the present invention encompasses the peptides constituted by or composed of a peptide sequence coded by the nucleotide sequences according to the invention as well as fragments of these peptides. It also encompasses the peptides which differ from the latter by one or more amino acids and which have the same function. These peptides can correspond to modifications such as those known with muteins or to allelic variations. In fact it has been shown in particular that certain genetic segments coding for the variable regions of chains of T receptors in man were subjected to a phenomenon of genetic polymorphism called allelic variation (25). The present invention encompasses the peptides resulting from this phenomenon.
The nucleotide sequences according to the invention have been obtained according to the following stages:
isolation of the RNA's of peripheral lymphocytes of an individual;
obtaining the complementary DNA using reverse transcriptase and a primer A which is specific to the C.alpha. region (SEQ ID No. 20);
genetic amplification (by Anchored Polymerase Chain Reaction or A-PCR) using a DNA polymerase, a poly C primer (SEQ ID No. 21) and a primer B which is specific to the C.alpha. region (SEQ ID No. 22);
a new amplification by A-PCR using DNA polymerase and a primer C which is specific to the C.alpha. region (SEQ ID No. 23);
insertion in a plasmid vector;
transformation of a bacterial host with the recombinant vector;
screening of recombinant bacterial colonies with a labelled oligonucleotide D which is specific to C.alpha. (SEQ ID No. 24);
extraction of plasmids from positive colonies;
and sequencing of DNA fragments containing the C.alpha. region.
The present invention can be reproduced, in particular, by bispecific genetic amplification (polymerase chain reaction or PCR) by starting with the peripheral lymphocytes which express the mRNA including the variable or junctional segments corresponding to sequences ID No. 1 to 13 and 14 to 19 of the invention or alternatively by applying this PCR technique to genomic DNA of any somatic cell of an individual taken at random. The invention can also be reproduced by preparing the above genetic sequences by the chemical synthesis of oligonucleotides.
The peptides according to the invention can be obtained by standard peptide synthesis. They can also be obtained by the application of known genetic engineering techniques including the insertion of a DNA sequence coding for a peptide according to the invention into an expression vector such as a plasmid and the transformation of cells with this expression vector.
Therefore a subject of the present invention is also plasmids and expression vectors containing a DNA sequence coding for a peptide according to the invention as well as the hosts transformed with this vector.
Also a subject of the present invention is antibodies, and, in particular, monoclonal antibodies directed, against an antigenic determinant belonging to or composed of a peptide according to the invention.
The monoclonal antibodies may be obtained by any of the techniques which allow the production of antibody molecules from cell line culture. These techniques include different techniques using hybridomas.
The antibody production may be obtained in animals by the immunization of the animals by injection with the peptides or fragments according to the invention, whether they be natural, recombinant or synthetic, optionally after coupling to an immunogen such as tetanic anatoxin, or also by injection of human T lymphocytes expressing the corresponding sequences at their surface, including recombinant cells transfected with the corresponding coding sequences.
Also a subject of the present invention is hybridomas producing monoclonal antibodies directed against the polypeptides according to the invention.
The present invention also encompasses the fragments and the derivatives of monoclonal antibodies according to the invention which are reactive with defined variable regions of T-cell receptors. These fragments are, in particular, the F(ab').sub.2 fragments which can be obtained by the enzymatic cleavage of antibody molecules with pepsin, the Fab' fragments which can be obtained by reduction of the disulphide bridges of F(ab').sub.2 fragments and the Fab fragments which can be obtained by the enzymatic cleavage of antibody molecules with papain in the presence of a reducing agent. These fragments can also be obtained by genetic engineering.
The monoclonal antibody derivatives are for example antibodies or fragments of these antibodies to which labellers such as a radio-isotope are attached. The monoclonal antibody derivatives are also antibodies or fragments of these antibodies to which therapeutically active molecules are attached, in particular, cytotoxic compounds.
The products of the invention have several uses in the field of diagnostics and in the field of therapeutics.
1--Uses in the field of diagnostics
The oligonucleotides contained in the nucleotide sequences according to the invention can be used to constitute detection probes (generally at least 10 nucleotides) which are capable of hybridizing with a variable region of the .alpha.-chain or primers for the amplification of DNA (generally containing at least 15 nucleotides and preferably at least 17 nucleotides) which are capable of being linked to a sequence to be amplified.
Thus the oligonucleotides are used in the diagnosis of immune disorders by detecting the presence of nucleic acid sequences which are homologues of a gene coding for the variable regions of .alpha.-chains of T-cell receptors in the mRNA of a sample from a patient. Different methods can be used to establish a connection between the expression of T-cell genes and an illness. These methods include:
a--the production and analysis of cDNA expression libraries obtained from T-cells connected with the illness to determine the frequency of dominant genes;
b--Southern blot analysis of samples of genomic DNA to determine whether genetic polymorphisms or rearrangements of the genes coding for the T-cell receptors exist;
c--the analysis of samples by obtaining cDNA, amplification by PCR and hybridization with labelled probes;
d--the hybridization in situ of T-cells without culture of T-cells beforehand.
The primers are used in PCR reactions in a method such as that defined in c above.
The monoclonal antibodies, the fragments or the derivatives of these antibodies according to the invention, in particular the anti V.alpha. antibodies, can be used to study T-type immune responses, for example in the field of the auto-immune diseases of oncology, of allergies, of transplants and of infectious diseases. In particular, the directory of different variable .alpha. segments of the T receptor can be studied, whether it be blood or tissue T-cells. In a general fashion the techniques used can be in vitro or in vivo methods.
With in vitro methods, the samples used can be samples of body fluids or tissue samples. The techniques used can include in particular flow cytofluorimetry to analyse blood T lymphocytes or labelling with immunoperoxidase on an anatomopathological section to study the lymphocytes infiltrating the tissues.
With in vivo methods, the antibodies, their fragments or their derivatives are administered by the usual routes, for example by intravenous route, and the immunospecific linkages are detected. This can be obtained for example in the case where an antibody is used which is labelled with a radio-isotope.
2--Uses in the therapeutic field
The oligonucleotides contained in the nucleotide sequences according to the invention can be used in therapeutics as anti sense oligonucleotides. In fact it is known that it is possible in vitro to inhibit the expression of a transcript gene in human lymphocytes by incubating these lymphocytes with an anti sense oligonucleotide specific to the gene in question (26). These anti sense oligonucleotides generally contain at least 10 and, preferably, at least 16 nucleotides. These anti sense oligonucleotides can be in particular the inverted and complemented sequences corresponding to 20 nucleotides upstream from the initiation site of the translation (ATG). The significance of the use in vitro of anti sense oligonucleotides specific to a V.alpha. or J.alpha. genetic segment is to abolish (or strongly diminish) the expression of a T receptor containing this V.alpha. or J.alpha. segment and thus to obtain a phenomenon of clonal deletion at the level of the specific reactivity of T lymphocytes. The anti sense oligonucleotides can not only be used in vitro on human T lymphocytes which are then reinjected, but also in vivo by local or systemic injection preferably after modification to increase the stability in vivo and the penetration into the T lymphocytes of these oligonucleotides.
The monoclonal antibodies according to the invention, in particular the anti V.alpha. antibodies can be used to modulate the immune system. It is in this way that the antibodies can be administered to block the interaction of the effector T-cells with their specific antigen. Anti T receptor antibodies linked for example to a cytotoxic molecule or a radio-isotope can also be administered in a way so as to obtain a clonal deletion, thanks to the specific fixation on an .alpha. chain of a T-cell receptor. The monoclonal antibodies according to the invention can be used in therapeutics at low mitogenic concentrations so as to activate, in a specific fashion, certain sub-assemblies of T-cells or can be used at much higher concentrations to fix them to the receptors concerned and thus label these sub-assemblies with a view to their elimination by the reticuloendothelial system. An important criterion in the treatment of an illness is the ability to modulate the sub-assemblies of T-cells linked with an illness. The exact nature of this therapeutic modulation, namely blocking or suppressing a particular sub-assembly of T-cells or on the contrary stimulating and activating a particular sub-assembly, will depend on the illness in question and the specific sub-assembly of T-cells concerned.
This type of treatment has an advantage over current treatments using antibodies such as the treatment with anti CD3 antibodies in patients having had a kidney transplant and having a rejection problem, given that thanks to the invention there will be no modulation of the totality of the T-cell population but only of the sub-assembly of T-cells expressing the .alpha. sub-family specific to the T-cell receptors.
Moreover, as the response of T-cells is often oligoclonal, it is generally convenient to use "cocktails" of several antibodies in therapeutics.
In addition anti V.alpha. antibodies can be used to select T lymphocytes in vitro, for example by passing through a column containing spheres carrying the antibody. This separation of certain T lymphocytes can be used with a view to culturing these lymphocytes before reinjection into the patient.
Moreover, all or part of the peptide sequences according to the invention can be used in therapeutics, that is to say the peptide sequences coded by the nucleotide sequences according to the invention or fragments of these sequences (generally containing at least 8 to 10 amino acids). These sequences or these fragments, administered to humans or animals, can act as a decoy, that is to say they fix themselves on the epitope carried by the harmful antigen and stop the reaction of normal T-cells with the antigen, preventing in this way the development of an illness which is aggressive towards the self determinants. They can also be used as immunogens in the manufacture of vaccines (optionally after conjugation with protein carriers).

The present invention will be described in greater detail hereafter by referring to the annexed figures in which:
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A to E show in a line both a known V sequence and a partial sequence of an extension according to the invention for the respective sequences SEQ ID No. 6 to 10, marked IGRa 08 to IGRa 12. In these figures, the numbering of nucleotides starts at the ATG initiation codon (which is underlined). The dots indicate identical nucleotides. The sequences which are assumed to be the leader sequences have a line over them.
FIG. 2 shows in a line the new J.alpha. sequences (SEQ ID No. 12, 13 and 14 to 19) marked IGRJa 01, 02 and 04 to 09. In these sequences the recombination signals of the germinal line are underlined. The amino acids corresponding to highly preserved codons are marked above the sequences. The codons corresponding to a substitution in one position of a preserved amino acid are underlined twice.
FIG. 3 shows the Southern blot analyses of the genomic DNA treated with a restriction enzyme using probes specific to sequences SEQ ID No. 1 to 5. The restriction enzymes used are EcoRI (column R), Hind III (column H) and Bam III (column B). On this figure the triangles mark the position of DNA fragments hybridizing in a specific fashion with C.alpha..
FIG. 4 represents the detection by autoradiography of amplified transcripts of TCR .alpha. chains expressed by the peripheral lymphocytes of a healthy individual and of a co-amplified .beta.-actin control.

I--OBTAINING THE CDNA AND AMPLIFICATION BY PCR
The peripheral lymphocytes of an individual are used as the DNA source. The total RNA was prepared according to the method using guanidinium isothiocyanate and caesium chloride (Chirgwin (10)) or according to a one-stage method by extraction with guanidinium isothiocyanate, phenol and chloroform (Chomcyznski (11)).
The first cDNA strand was synthesized in a final volume of 50 microliters at a temperature of 42.degree. C. for 1 hour using 5 micrograms of total RNA, reverse transcriptase and a primer A which is specific to the C.alpha. region constituted by the sequence 5'-GTTGCTCCAGGCCACAGCACTG (SEQ ID No. 20). This material was then purified by extraction with phenol/chloroform and precipitation with ammonium acetate. After selecting a 0.45/1 kb fraction on agarose gel, the addition of a dG end is carried out on the RNA/cDNA hetero complex in a CoCl.sub.2 addition buffer with 14 units of terminal deoxynucleotidyl transferase (TdT) for 30 minutes at 37.degree. C. The reaction was stopped by maintenance at 70.degree. C. for 10 minutes. 1N NaOH (1/3 volume) was added and the sample was incubated at 50.degree. C. for 1 hour to hydrolyze the RNA, then neutralized with Tris HCl 2M pH 8 and 1N HCl. After extraction with a phenol/chloroform mixture the first cDNA strand at end G was precipitated with ethanol and subjected to an amplification using the PCR technique (Polymerase Chain Reaction described by Saiki et al. (12)) in a final volume of 100 microliters containing 50 mM of KCl, 10 mM of Tris-Cl pH 8.3, 1.5 mM of MgCl.sub.2, 0.1% (weight/volume) of gelatine, 200 micromoles of dNTP, 2.5 units of Taq polymerase and 100 picomoles of two primers. The two primers used are, on the one hand a poly-C primer (5'-GCATGCGCGCGGCCGCGGAGG-14C) (SEQ ID No.21) described by Loh et al. (13) as well as a primer B specific to the C.alpha.region (5'-GTCCATAGACCTCATGTCCAGCACAG) (SEQ ID No. 22).
25 amplification cycles are carried out followed by a final 15 minute elongation period at 72.degree. C. Each cycle includes a denaturation stage at 92.degree. C. for 1 minute, a hybridization stage at 55.degree. C. for 2 minutes and an elongation period at 72.degree. C. for 4 minutes. The amplified products are then precipitated with ethanol, resuspended in 30 mM of sodium acetate pH 5, 50 mM NaCl, 1 mM ZnCl.sub.2, glycerol 5% by volume and 1/10 of this material is purified as a function of size on a 1% low melting point agarose gel.
A second amplification phase is then carried out directly on approximately 10% of the band containing the agarose following the same conditions as previously, except that the primer 5'-ATACACATCAGAATTCTTACTTTG (SEQ ID No. 23) is used as primer C which is specific to the C.alpha. region. The reaction mixture is then precipitated with ethanol and resuspended in 60 .mu.l of H.sub.2 O.
II--Cloning and Sequencing of cDNA's
1/3 of the product of the second amplification is digested with Sac II, separated on 1% agarose gel and purified by absorption on glass beads. The material is inserted in the Bluescript SK.sup.+ vector (Stratagene, La Jolla, U.S.A.) and the recombinants obtained are used to transform the XL1-blue strains of E. Coli (Stratagene). After sedimentation in the presence of X-gal and IPTG, a test is carried out on the white colonies using a "dot blot" technique and a third oligonucleotide specific to the C.alpha. region (5'-GTCACTGGATTTAGAGTCT) (SEQ ID No. 24) labelled with .sup.32 P is used as a probe. The plasmid DNA of positive colonies is extracted and sequencing takes place under the two strands by the process of termination of the dideoxy chain (Sanger et al. (14)) with Sequenase 2.0 (United States Biochemicals, Cleveland, U.S.A.) following the supplier's recommendations. With the exception of the Sequence SEQ ID No. 5, all the nucleotide sequences were determined on the two strands using at least two distinct clones of cDNA.
The sequences obtained were compared with published V.alpha. and J.alpha. sequences using the method developed by Lipman and Pearson (15). The presumed start codons were identified by searching for the presence of the Kozak consensus sequence for the initiation sites of translations in the eukaryotic cells (Kozak (16)). The presence of hydrophobic leader sequences of the N-terminal side was detected by analysis of the hydrophobicity according to the method described by Kyte (17).
III--Southern Blot Analysis
The DNA was extracted from the human erythroleucemic cell line K562 and digested with one of the following restriction enzymes: EcoR I, BamH I or Hind III. The DNA (15 micrograms) was subjected to electrophoresis on 0.7% agarose and transferred onto Nylon membranes as described by Triebel et al. (18). The hybridizations were carried out at 65.degree. C. with 6.times.SSC, 0.5% of SDS, 5.times.Denhardt's and 100 micrograms of denatured salmon sperm DNA for 16 hours. The membranes were washed at 65.degree. C. with 2.times.SSC, 0.2% of SDS.
As V.alpha. specific probes, are used the probes obtained by amplification of V-J-C cDNA (>500 bp) containing V.alpha. fragments corresponding to sequences SEQ ID No. 1 to 5 using as a primer the poly-C primer and the C primer. The probes were purified on 1% agarose gel. DNA probes labelled with .sup.32 P were prepared from fragments purified on agarose by the Feinberg method (19).
IV--Results
By using the A-PCR method, 308 cDNA which hybridize with the C.alpha. clone were cloned, then sequenced. Among these, 172 cDNA correspond to the V-J-C.alpha. variable regions only.
The V.alpha. and J.alpha. sequences of the invention are shown in the list of sequences under SEQ ID No. 1 to 11 and SEQ ID No. 12, 13 and 14 to 19 respectively. The sequences SEQ ID No. 2 to 5 correspond to the new sub-families (designated V.alpha.25, V.alpha.26, V.alpha.27 and V.alpha.29 respectively) while the sequences SEQ ID No. 1 and 6 to 11 correspond to extensions of known V segments.
1. V.alpha. sequences corresponding to new sub-families
The Southern blot analyses of germinal line DNA subjected to digestion by endonucleases, using V-J-C.alpha. probes containing V.alpha. fragments corresponding to sequences SEQ ID No. 2 to 5 were carried out in "low stringency" hybridization conditions to identify the number of V.alpha. genetic segments belonging to each family and to characterize the DNA restriction fragments carrying these V.alpha. genetic segments. The representative results are shown in FIG. 3.
These analyses show that the sub-family corresponding to the sequence SEQ ID No. 3 includes at least two genetic segments while the other sequences (SEQ ID No. 2, No. 4 and No. 5) probably correspond to unique members.
The sizes of the germinal DNA restriction fragments are as follows:
SEQ ID No. 2: EcoR I 2.2 kb, Hind III 4.8 and 5.7 kb, BamH I 25 kb
SEQ ID No. 3: EcoR I 4.6 and 7.5 kb, Hind III 4.2 and 6.4 kb, BamH I 23 and 4.5 kb SEQ ID No. 4: EcoR I 7.6 kb, Hind III 18 kb, BamH I 9 and 0.9 kb SEQ ID No. 5: EcoR I 5.9 and 4.8 kb, Hind III 6.6 kb, BamH I 6.5 kb.
2. Sequences corresponding to extensions of known V sequences
SEQ ID No. 1 (IGR a 02) corresponds to an extension of the 5' side of the LINV sequence (171 bp) (mengle-Gaw (20)): This sequence defines the sub-family provisionaly designated V.alpha.w24.
SEQ ID No. 6 (IGR a 08): this sequence corresponds to an extension of the 5' side of the V.alpha.1 AE11 clone sequence (Klein et al. (21)). The two straight line sequences are represented in FIG. 1A.
SEQ ID No. 7 (IGR a 09): This sequence corresponds to an extension coding for the NH2 terminal end of the V.alpha.2 AF110 sequence (Klein already quoted). The two straight line sequences are represented in FIG. 1B. The sequence ID No. 7 corresponds to a consensus sequence. The existence of a T instead of a C is observed in position 206.
SEQ ID No. 8 (IGR a 010): This sequence corresponds to an extension of the 5' region of the V.alpha. HAP35 clone (Yoshikai (22)). The two straight line sequences are represented in FIG. 1C. The sequence ID No. 8 corresponds to a consensus sequence. The existence of a G instead of an A in position 307 and the existence of a T instead of a C in position 360 have been observed.
SEQ ID No. 9 (IGR a 11): This sequence corresponds to an extension of the 3' side of the V.alpha.7 HAP12 sequence (Yoshikai already quoted). The straight line of the sequences is represented in FIG. 1D. The sequence ID No. 9 corresponds to a consensus sequence. The existence of a C instead of a T in position 86 has been observed.
SEQ ID No. 10 (IGR a 12): This sequence includes the complete coding region of a gene of the V.alpha.22 sub-family which had been previously identified by the partial sequence (113 bp) AC9 (Klein already quoted). The two straight line sequences are represented in FIG. 1E.
SEQ ID No. 11 (IGR a 13): This sequence corresponds in part to the HAVT 32 and HAVT 35 clones (belonging to the V.alpha.16 (8) sub-family and which have been described as pseudogenes. In fact, following the addition of a nucleotide in position 108, the SEQ ID No. 11 codes for an original variable region of a T lymphocyte receptor. Moreover, this sequence is equivalent to a sequence HSTCAYM (Klein et al. (21)) for the coding part. However, the sequence SEQ No. 11 is the only one which is complete and coding.
3. J.alpha. sequences
The set of new J.alpha. sequences are represented in FIG. 2. Among the 8 J.alpha. segments, the majority of them have a highly preserved amino acid sequence FGXGT of J.alpha. segments as described by Yoshikai already quoted. However, for the IGRJa 07 segment the threonine residue is replaced by an isoleucine residue.
In addition, instead of a phenylalanine residue a cysteine residue is found in IGRJa 02G.
The present invention also aims at providing specific oligonucleotides of different V.alpha. sub-families, which can be used as primers for the amplification of DNA corresponding to these different V.alpha. sub-families, with a view, for example, of a study of the expression of certain V.alpha. sub-families in a patient and finally of a diagnosis of immune disorders, as indicated above.
The predominant expression of certain V.alpha. sub-families has already been studied using an incomplete range of oligonucleotides. In this way Nitta et al. (29) have described the predominant expression of V.alpha.7 genes in the lymphocytes infiltrating the tumours. Moreover, Sottini et al. (30) have described the study of the directory of V.alpha.'s, in patients suffering from rheumatoid arthritis.
The present invention aims to provide a complete range of oligonucleotides allowing the study, of both known V.alpha. sub-families and new V.alpha. sub-families of the invention and which are completely specific to each sub-family. Thus the oligonucleotides have been chosen and synthesized to this end and to the requirements of modifications of one or two nucleotides which have been introduced relative to the natural sequences to reduce the cross-reactions between sub-families.
Thus a subject of the present invention is also oligonucleotides which can be used as primers for the amplification of DNA corresponding to the variable regions of .alpha. chains of T-cell receptors, chosen from the sequences SEQ ID No. 25 to 53.
Also a subject of the present invention is the use, as primers for the amplification of DNA corresponding to the variable regions of .alpha. chains of T-cell receptors, of oligonucleotides chosen from the sequences SEQ ID No. 25 to 53.
Also a subject of the present invention is a detection process of nucleotide sequences coding for the V.alpha. segments of T receptors or of cDNA corresponding to transcription products of the latter, in a biological sample, characterized in that it includes:
a) the amplification of DNA with at least one pair of primers formed by one of the oligonucleotides chosen from the sequences SEQ ID No. 25 to 53 and one oligonucleotide belonging to segment C.alpha., and
b) the detection of amplified sequences with a C.alpha. probe.
The oligonucleotide belonging to a C.alpha. segment used for the amplification can be, in particular, chosen from the sequences SEQ ID No. 54 and 55.
To check the efficiency of the amplification, the operation is preferably carried out in the presence of a pair of control primers and the corresponding control sequence amplified using a corresponding control probe is detected.
This pair of control primers can correspond to two C.beta. segments, for example the C.beta.F and C.beta.K primers corresponding to sequences SEQ ID No. 59 and 61. Then a C.beta. detection probe is used (corresponding for example to the sequence SEQ ID No. 62). But this pair of primers can also be constituted by two primers belonging to .beta.-actin, notably those corresponding to sequences SEQ ID No. 57 and 58. Then a detection probe corresponding to a sequence of .beta.-actin, such as the sequence SEQ ID No. 59, is used.
Also a subject of the present invention is a diagnostic kit for the implementation of the process defined previously, which includes:
a) at least one oligonucleotide chosen from the sequences SEQ ID No. 25 to 53,
b) a C.alpha. primer,
c) a C.alpha. probe.
In addition such a kit advantageously contains:
d) a pair of control primers,
e) a control probe.
This kit can contain in particular:
a) the group of 29 oligonucleotides corresponding to sequences SEQ ID No. 25 to 53,
b) a C.alpha. primer chosen from the sequences corresponding to sequences SEQ ID No. 54 and 55,
c) a pair of control primers for .beta.-actin having a sequence corresponding to sequences SEQ ID NO. 57 and 58 respectively,
d) a C.alpha. probe corresponding to the sequence SEQ ID No. 56,
e) a control probe for .beta.-actin corresponding to the sequence SEQ ID No. 59.
In the information given in the list of sequences for the sequences 25 to 59, the sequences SEQ ID No. 25 to 46 correspond to sequences belonging to clones of known V.alpha.1 to V.alpha.22 sub-families (available from the EMBL database) or to sequences which differ from them by one or two nucleotides.
The sequences SEQ ID No. 48, 49, 50, 51 and 53 correspond to sequences belonging to clones of new sub-families of the invention, corresponding to sub-families provisionally designated V.alpha.w24, V.alpha.w25, V.alpha.w26, V.alpha.w27 and V.alpha.w29 (w indicating that the designation is pending definitive designation).
The sequences SEQ ID No. 47 and 52 correspond to sequences belonging to clones IGRa01 and IGRa06 respectively of known sub-families but having not yet received definitive designation (V.alpha. w23 and V.alpha. w28 respectively) one member element of which has already been described (Hinkkanen A., et al. (31) and Bernard O. et al. (32) respectively). The complete sequence of IGRa06 has not yet been published.
The sequences SEQ ID No. 54 and 55 are two examples of oligonucleotides which can be used as C.alpha. primers for amplification.
The sequence SEQ ID No. 56 is the sequence of a C probe which can be used for the detection of amplified DNAs.
The sequences SEQ ID No. 57, 58 and 59 are respectively the sequences of a pair of oligonucleotides belonging to the sequence of .beta.-actin which can be used to check the amplification and the sequence of a probe for detecting the corresponding amplified DNAs.
In the list of sequences the position indicated is the position of the 5' end counting from the predicted initiation site of the ATG translation. In the case where the sequences are incomplete (unknown 5'region), the position (marked with an asterisk) is given relative to the first nucleotide of the sequence. The underlined nucleotides correspond to mismatches introduced relative to the natural sequence.
The oligonucleotides were synthesized with an Applied Biosystems 381 A automated DNA synthesizer using the .beta.-cyano-ethylphosphoramidite method (Sinha N. et al. (33)) and following the protocol recommended by the manufacturer. The oligonucleotides were detritylated in the apparatus, cleaved from the support and deprotected with ammonia (at 60.degree. C. for 5 hours). The crude products were purified by reverse phase high pressure chromatography on a .mu.-bondapak C18 column using an acetonitrile gradient (9 to 15%) in a 0.01M triethylammonium acetate buffer at pH 5.5.
The amplification carried out using the primers according to the invention can be, in particular, the technique of amplification by PCR (Polymerase Chain Reaction) as described by Saiki et al. (12) and in Patents U.S. Pat Nos. 4,683,195, 4,683,202, 4,889,818.
For the PCR, a double strand DNA can be used which is denatured or a cDNA obtained from RNA using reverse transcriptase as mentioned above.
The polymerization agent is a DNA polymerase, in particular, Taq polymerase.
Generally the amplification cycle is repeated 24 to 39 times.
The probes which are used for detecting the amplified sequences can be obtained by labelling the oligonucleotides with radio-active isotope, which leads to detection by autoradiography, or by conjugation with an enzyme such as peroxidase (ECL Amersham system), alkaline phosphatase or .beta.-galactosidase (Tropix Ozyme system), which leads to detection by chemiluminescence.
The following example illustrates the implementation of the detection process according to the invention.
The peripheral lymphocytes of a healthy individual were prepared by density gradient centrifugation. The total DNA was extracted according to a one-stage method by extraction with guanidium isothiocyanate, phenol and chloroform (Chomczynski, 11). The complementary DNA was synthesized in a final volume of 20 .mu.l at 42.degree. C. for one hour using 1 to 5 .mu.g of total RNA, the reverse transcriptase and the C.alpha.B primer (1.25 .mu.M).
The material obtained was then heated at 95.degree. C. for 3 minutes before being subjected to an amplification according to the PCR technique using in parallel each of the specific V.alpha. primers corresponding to sequences SEQ ID No. 25 to 53 and the C.alpha.B primer specific to the C.alpha. region (SEQ ID No. 55). This amplification was carried out in a final volume of 10 .mu.l per tube containing 50 mM of KCl, 10 mM of tris-HCl pH 8.3, 1.5 mM of MgCl.sub.2, 0.1% (weight/volume) of gelatine, 200 .mu.M of dNTP, 0.25 units of Taq polymerase and 0.25 .mu.M of each primer. A control amplification was carried out in each tube from 25 mN of a DNA fragment of .beta.-actin of 877 base pairs prepared by PCR and Act 1 and Act 2 primers (SEQ ID No. 57 and 58) specific to actin. 30 amplification cycles were carried out followed by a final elongation stage of 5 minutes at 72.degree. C. Each cycle included a denaturation stage at 94.degree. C. for one minute, a hybridization stage at 65.degree. C. for one minute and an elongation period at 72.degree. C. for one minute.
The products obtained were separated by electrophoresis on 2% agarose gel, transferred onto nylon membranes in an alkaline buffer and hybridized simultaneously with the C.alpha.C oligonucleotide probes (SEQ ID No. 56) and Act 3 (SEQ ID No. 59) labelled with .sup.32 P by the polynucleotidyl T4 kinase enzyme. The hybridization was carried out at 42.degree. C. for 16 hours in a buffer containing 6.times.SSC, 0.5% SDS, 5.times.Denhardt's, 0.05% NaH.sub.2 PO.sub.4 and 100 .mu.g/ml of denatured salmon sperm DNA. The membranes were then washed with SSC 6.times., 20 mM NaH.sub.2 PO.sub.4, twice at ambient temperature for 5 minutes and once at 50.degree. C. for 30 minutes then autoradiographed.
The results obtained are shown in FIG. 4.
The actin control (band of 877 base pairs) allows the amplification to be verified in all wells. A specific signal appears below this band the size of which corresponds to the size of corresponding amplified fragments, each fragment having a length corresponding to the distance between the locus of the specific V.alpha. oligonucleotide and the C.alpha. primer.
With the individual tested, FIG. 4 shows the preferential expression of certain genetic segments defined relative to the others. For example, the V.alpha.27, 28 and 29 sub-families are less well represented than the V.alpha.2, 3 and 6 sub-families.
REFERENCES
1. Meuer, S. C., et al., J. Exp. Med. 1983. 157:705.
2. Moingeon, P., et al., Nature 1986a. 323:638.
3. Brenner, M. B., et al., Nature 1986. 322:145.
4. Bank, I., et al., Nature 1986. 322:179.
5. Davis, M. M., et al., Nature 1988. 334:395.
6. Crews, S., et al., Cell 1981. 25:59.
7. Concannon, P., et al., Proc. Natl. Acad. Sci. USA. 1986. 83:6598.
8. Kimura, N., et al., Eur. J. Immunol. 1987. 17:375.
9. Wilson, R. K., et al., Immunological Reviews 1988c. 101:149.
10. Chirgwin, J. M., et al. Biochemistry 1979. 18:5294.
11. Chomczynski, P., et al., Anal. Biochem. 1987. 162:156.
12. Saiki, R. K., et al., Science 1988. 239:487.
13. Loh, E. Y., et al., Science 1989. 243:217.
14. Sanger, F., et al., Proc. Natl. Acad. Sci. USA 1977. 74:5463.
15. Lipman, D. J., et al., Science 1985. 227:1435.
16. Kozak, M., Nucl. Acids Res. 1984. 12:857.
17. Kyte, J., et al., R. F., J. Mol. Biol. 1982. 157:105.
18. Triebel, F., et al., J. Immun. 1988. 140:300.
19. Feinberg, A. P., et al., Anal. Bichem. 1983. 132:6.
20. Mengle-Gaw, L., et al., The EMBO Journal, 1987. 6:2273.
21. Klein, M. H., et al., Proc. Natl. Acad. Sci. USA 1987. 84:6884.
22. Yoshikai, Y., et al., J. Exp. Med. 1986. 164:90.
23. Wandenbark, A., et al., Nature, 341, 541.
24. Janeway, C., Nature, 341, 482.
25. Li, Y., J. Exp. Med., 171, 221.
26. Acha-Orbea, H., EMBO Journal, 1990,9, 12, 3815.
27. Kappler, J., Science 244, 811.
28. Choi, Y., PNAS, 86, 8941.
29. Nitta T. et al., Science 1990, 249, 672.
30. Sottini A. et al., Eur. J. Immunol., 1991, 21, 461.
31. Hinkkanen A. et al., Immunogenetics, 1989, 29, 131.
32. Bernard O. et al., Oncogene, 1988, 2, 195.
33. Sinha N. et al., Nucleic Acids Res. 1984, 12, 4539.
__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 62(2) INFORMATION FOR SEQ ID NO: 1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 371(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA TO mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a O2(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V.alpha. w24(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:AGTCAACTTCTGGGAGCAGTCTCTGCAGAATAAAA35ATGAAAAAGCATCTGACGACCTTCTTGGTGATTTTG71MetLysLysHisLeuThrThrPheLeuValIleLeu1510TGGCTTTATTTTTATAGGGGGAATGGCAAAAACCAA107TrpLeuTyrPheTyrArgGlyAsnGlyLysAsnGln1520GTGGAGCAGAGTCCTCAGTCCCTGATCATCCTGGAG143ValGluGlnSerProGlnSerLeuIleIleLeuGlu253035GGAAAGAACTGCACTCTTCAATGCAATTATACAGTG179GlyLysAsnCysThrLeuGlnCysAsnTyrThrVal4045AGCCCCTTCAGCAACTTAAGGTGGTATAAGCAAGAT215SerProPheSerAsnLeuArgTrpTyrLysGlnAsp505560ACAATCATGACTTTCAGTGAGAACACAAAGTCGAAC251ThrGlyArgGlyProValSerLeuThrIleMetThr6570GGAAGATATACAACTGGGAGAGGTCCTGTTTCCCTG287PheSerGluAsnThrLysSerAsnGlyArgTyrThr7580GCAACTCTGGATGCAGACACAAAGCAAAGCTCTCTG323AlaThrLeuAspAlaAspThrLysGlnSerSerLeu859095CACATCACAGCCTCCCAGCTCAGCGATTCAGCCTCC359HisIleThrAlaSerGlnLeuSerAspSerAlaSer100105TACATCTGTGTG371TyrIleCysVal110(2) INFORMATION FOR SEQ ID NO: 2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 400(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA TO mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 03(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. w 25(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:GACTCTAAGCCCAAGAGAGTTTCTTGAAGCAAAAAAAAAA40AAAACCCATTCAGGAAATAATTCTTTGCTGATAAGG76ATGCTCCTTGAACATTTATTAATAATCTTGTGGATG112MetLeuLeuGluHisLeuLeuIleIleLeuTrpMet1510CAGCTGACATGGGTCAGTGGTCAACAGCTGAATCAG148GlnLeuThrTrpValSerGlyGlnGlnLeuAsnGln1520AGTCCTCAATCTATGTTTATCCAGGAAGGAGAAGAT184SerProGlnSerMetPheIleGlnGluGlyGluAsp253035GTCTCCATGAACTGCACTTCTTCAAGCATATTTAAC220ValSerMetAsnCysThrSerSerSerIlePheAsn4045ACCTGGCTATGGTACAAGCAGGACCCTGGGGAAGGT256ThrTrpLeuTrpTyrLysGlnAspProGlyGluGly505560CCTGTCCTCTTGATAGCCTTATATAAGGCTGGTGAA292ProValLeuLeuIleAlaLeuTyrLysAlaGlyGlu6570TTGACCTCAAATGGAAGACTGACTGCTCAGTTTGGT328LeuThrSerAsnGlyArgLeuThrAlaGlnPheGly7580ATAACCAGAAAGGACAGCTTCCTGAATATCTCAGCA364IleThrArgLysAspSerPheLeuAsnIleSerAla859095TCCATACCTAGTGATGTAGGCATCTACTTCTGTGCT400SerIleProSerAspValGlyIleTyrPheCysAla100105(2) INFORMATION FOR SEQ ID NO: 3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 339(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 04(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. w26(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:AGCTAAGGGATGGAGACTGTTCTGCAAGTACTCCTA36MetGluThrValLeuGlnValLeuLeu15GGGATATTGGGGTTCCAAGCAGCCTGGGTCAGTAGC72GlyIleLeuGlyPheGlnAlaAlaTrpValSerSer101520CAAGAACTGGAGCAGAGTCCTCAGTCCTTGATCGTC108GlnGluLeuGluGlnSerProGlnSerLeuIleVal2530CAAGAGGGAAAGAATCTCACCATAAACTGCACGTCA144GlnGluGlyLysAsnLeuThrIleAsnCysThrSer354045TCAAAGACGTTATATGGCTTATACTGGTATAAGCAA180SerLysThrLeuTyrGlyLeuTyrTrpTyrLysGln5055AAGTATGGTGAAGGTCTTATCTTCTTGATGATGCTA216LysTyrGlyGluGlyLeuIlePheLeuMetMetLeu6065CAGAAAGGTGGGGAAGAGAAAAGTCATGAAAAGATA252GlnLysGlyGlyGluGluLysSerHisGluLysIle707580ACTGCCAAGTTGGATGAGAAAAAGCAGCAAAGTTCC288ThrAlaLysLeuAspGluLysLysGlnGlnSerSer8590CTGCATATCACAGCCTCCCAGCCCAGCCATGCAGGC324LeuHisIleThrAlaSerGlnProSerHisAlaGly95100105ATCTACCTCTGTGGA339IleTyrLeuCysGly110(2) INFORMATION FOR SEQ ID NO: 4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 335(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 05(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. w27(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:AGAAAAAAAAAATGAAGAAGCTACTAGCAATGATCCTGTG40GCTTCAACTAGACCGGTTAAGTGGAGAGCTGAAAGTG77GAACAAAACCCTCTGTTCCTGAGCATGCAGGAGGGA113GluGlnAsnProLeuPheLeuSerMetGlnGluGly1510AAAAACTATACCATCTACTGCAATTATTCAACCACT149LysAsnTyrThrIleTyrCysAsnTyrSerThrThr1520TCAGACAGACTGTATTGGTACAGGCAGGATCCTGGG185SerAspArgLeuTyrTrpTyrArgGlnAspProGly253035AAAAGTCTGGAATCTCTGTTTGTGTTGCTATCAAAT221LysSerLeuGluSerLeuPheValLeuLeuSerAsn4045GGAGCAGTGAAGCAGGAGGGACGATTAATGGCCTCA257GlyAlaValLysGlnGluGlyArgLeuMetAlaSer505560CTTGATACCAAAGCCCGTCTCAGCACCCTCCACATC293LeuAspThrLysAlaArgLeuSerThrLeuHisIle6570ACAGCTGCCGTGCATGACCTCTCTGCCACCTACTTC329ThrAlaAlaValHisAspLeuSerAlaThrTyrPhe7580TGTGCC335CysAla85(2) INFORMATION FOR SEQ ID NO: 5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 361(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 07(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. w29(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:GAAGCTGACTGGATATTCTGGCAGGCCAAGGATGGAGACT40MetGluThrCTCCTGAAAGTGCCTTCAGGCACCTTGTTGTGGCAG76LeuLeuLysValProSerGlyThrLeuLeuTrpGln510TTGACCTGGGTGGGAAGCCAACAACCAGTGCAGAGT112LeuThrTrpValGlySerGlnGlnProValGlnSer152025CCTCAAGCCGTGATCCTCCGAGAAGGGGAAGATGCT148ProGlnAlaValIleLeuArgGluGlyGluAspAla3035GTCACCAACTGCAGTTCCTCCAAGGCTTTATATTCT184ValThrAsnCysSerSerSerLysAlaLeuTyrSer404550GTACACTGGTACAGGCAGAAGCATGGTGAAGCACCC220ValHisTrpTyrArgGlnLysHisGlyGluAlaPro5560GTCTTCCTGATGATATTACTGAAGGGTGGAGAACAG256ValPheLeuMetIleLeuLeuLysGlyGlyGluGln6570ATGCGTCGTGAAAAAATATCTGCTTCATTTAATGAA292MetArgArgGluLysIleSerAlaSerPheAsnGlu758085AAAAAGCAGCAAAGCTCCCTGTACCTTACGGCCTCC328LysLysGlnGlnSerSerLeuTyrLeuThrAlaSer9095CAGCTCAGTTACTCAGGAACCTACTTCTGCGGG361GlnLeuSerTyrSerGlyThrTyrPheCysGly100105(2) INFORMATION FOR SEQ ID NO: 6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 569(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 08(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 1(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:TCAGTTTCTTCTTCCTGCAGCTGGTTGAGTTCTTTCCAGA40CAAAGACAAGTGACAAGAATTAGAGGTTTAAAAAGCAACC80AGATTCATCTCAGCAGCTTTTGTAGTTTTAAATAAGCAAG120GAGTTTCTCCAGCGAAACTTCCTCACACCTCTTGGTCTTG160GTCTCTTCAGACACTTTCCTTCCTGTTCTCTGGAGATCTT200GCAGAAAAGAGCCTGCAGTGTTTCCCTTGCTCAGCCATG239Met1CTCCTGGAGCTTATCCCACTGCTGGGGATACATTTT275LeuLeuGluLeuIleProLeuLeuGlyIleHisPhe510GTCCTGAGAACTGCCAGAGCCCAGTCAGTGACCCAG311ValLeuArgThrAlaArgAlaGlnSerValThrGln152025CCTGACATCCACATCACTGTCTCTGAAGGAGCCTCA347ProAspIleHisIleThrValSerGluGlyAlaSer3035CTGGAGTTGAGATGTAACTATTCCTATGGGGCAACA383LeuGluLeuArgCysAsnTyrSerTyrGlyAlaThr4045CCTTATCTCTTCTGGTATGTCCAGTCCCCCGGCCAA419ProTyrLeuPheTrpTyrValGlnSerProGlyGln505560GGCCTCCAGCTGCTCCTGAAGTACTTTTCAGGAGAC455GlyLeuGlnLeuLeuLeuLysTyrPheSerGlyAsp6570ACTCTGGTTCAAGGCATTAAAGGCTTTGAGGCTGAA491ThrLeuValGlnGlyIleLysGlyPheGluAlaGlu758085TTTAAGAGGAGTCAATCTTCCTTCAACCTGAGGAAA527PheLysArgSerGlnSerSerPheAsnLeuArgLys9095CCCTCTGTGCATTGGAGTGATGCTGCTGAGTACTTC563ProSerValHisTrpSerAspAlaAlaGluTyrPhe100105TGTGCT569CysAla110(2) INFORMATION FOR SEQ ID NO: 7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 330(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 09(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 2(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:AAATCCTTGAGAGTTTTACTAGTGATCCTGTGGCTT36LysSerLeuArgValLeuLeuValIleLeuTrpLeu1510CAGCTGAGCCGGGTTTGGAGCCAACAGAAGGAGGTG72GlnLeuSerArgValTrpSerGlnGlnLysGluVal1520GAGCAGAATTCTGGACCCCTCAGTGTTCCAGAGGGA108GluGlnAsnSerGlyProLeuSerValProGluGly253035GCCATTGCCTCTCTCAACTGCACTTACAGTGACCGA144AlaIleAlaSerLeuAsnCysThrTyrSerAspArg4045GGTTCCCAGTCCTTCTTCTGGTACAGACAATATTCT180GlySerGlnSerPhePheTrpTyrArgGlnTyrSer505560GGGAAAAGCCCTGAGTTGATAATGTCCATATACTCC216GlyLysSerProGluLeuIleMetSerIleTyrSer6570AATGGTGACAAAGAAGATGGAAGGTTTACAGCACAG252AsnGlyAspLysGluAspGlyArgPheThrAlaGln7580CTCAATAAAGCCAGCCAGTATGTTTCTCTGCTCATC288LeuAsnLysAlaSerGlnTyrValSerLeuLeuIle859095AGAGACTCCCAGCCCAGTGATTCAGCCACCTACCTC324ArgAspSerGlnProSerAspSerAlaThrTyrLeu100105TGTGCC330CysAla110(2) INFORMATION FOR SEQ ID NO: 8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 400(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 10(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 5(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:GCCAAACAGAATGGCTTTTTGGCTGAGAAGGCTGGGTCTA40CATTTCAGGCCACATTTGGGGAGACGAATGGAGTCA76MetGluSer1TCCCTGGGAGGTGTTTTGCTGATTTTGTGGCTTCAA112SerLeuGlyGlyValLeuLeuIleLeuTrpLeuGln51015GTGGACTGGGTGAAGAGCCAAAAGATAGAACAGAAT148ValAspTrpValLysSerGlnLysIleGluGlnAsn2025TCCGAGGCCCTGAACATTCAGGAGGGTAAAACGGCC184SerGluAlaLeuAsnIleGlnGluGlyLysThrAla3035ACCCTGACCTGCAACTATACAAACTATTCTCCAGCA220ThrLeuThrCysAsnTyrThrAsnTyrSerProAla404550TACTTACAGTGGTACCGACAAGATCCAGGAAGAGGC256TyrLeuGlnTrpTyrArgGlnAspProGlyArgGly5560CCTGTTTTCTTGCTACTCATACGTGAAAATGAGAAA292ProValPheLeuLeuLeuIleArgGluAsnGluLys657075GAAAAAAGGAAAGAAAGACTGAAGGTCACCTTTGAT328GluLysArgLysGluArgLeuLysValThrPheAsp8085ACCACCCTTAAACAGAGTTTGTTTCATATCACAGCC364ThrThrLeuLysGlnSerLeuPheHisIleThrAla9095TCCCAGCCTGCAGACTCAGCTACCTACCTCTGTGCT400SerGlnProAlaAspSerAlaThrTyrLeuCysAla100105110(2) INFORMATION FOR SEQ ID NO: 9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 386(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 11(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 7(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:GCCTTCTGCAGACTCCAATGGCTCAGGAACTGGGAATGCA40GTGCCAGGCTCGTGGTATCCTGCAGCAGATGTGGGGA77MetTrpGly1GTTTTCCTTCTTTATGTTTCCATGAAGATGGGAGGC113ValPheLeuLeuTyrValSerMetLysMetGlyGly51015ACTACAGGACAAAACATTGACCAGCCCACTGAGATG149ThrThrGlyGlnAsnIleAspGlnProThrGluMet2025ACAGCTACGGAAGGTGCCATTGTCCAGATCAACTGC185ThrAlaThrGluGlyAlaIleValGlnIleAsnCys3035ACGTACCAGACATCTGGGTTCAACGGGCTGTTCTGG221ThrTyrGlnThrSerGlyPheAsnGlyLeuPheTrp404550TACCAGCAACATGCTGGCGAAGCACCCACATTTCTG257TyrGlnGlnHisAlaGlyGluAlaProThrPheLeu5560TCTTACAATGTTCTGGATGGTTTGGAGGAGAAAGGT293SerTyrAsnValLeuAspGlyLeuGluGluLysGly657075CGTTTTTCTTCATTCCTTAGTCGGTCTAAAGGGTAC329ArgPheSerSerPheLeuSerArgSerLysGlyTyr8085AGTTACCTCCTTTTGAAGGAGCTCCAGATGAAAGAC365SerTyrLeuLeuLeuLysGluLeuGlnMetLysAsp9095TCTGCCTCTTACCTCTGTGCT386SerAlaSerTyrLeuCysAla100105(2) INFORMATION FOR SEQ ID NO: 10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 383(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA TO mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 12(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 22(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:TGTGACTTCTTCATGTTAAGGATCAAGACCATTATTTGGG40TAACACACTAAAGATGAACTATTCTCCAGGCTTA74MetAsnTyrSerProGlyLeu15GTATCTCTGATACTCTTACTGCTTGGAAGAACCCGT110ValSerLeuIleLeuLeuLeuLeuGlyArgThrArg1015GGAGATTCAGTGACCCAGATGGAAGGGCCAGTGACT146GlyAspSerValThrGlnMetGluGlyProValThr202530CTCTCAGAAGAGGCCTTCCTGACTATAAACTGCACG182LeuSerGluGluAlaPheLeuThrIleAsnCysThr3540TACACAGCCACAGGATACCCTTCCCTTTTCTGGTAT218TyrThrAlaThrGlyTyrProSerLeuPheTrpTyr455055GTCCAATATCCTGGAGAAGGTCTACAGCTCCTCCTG254ValGlnTyrProGlyGluGlyLeuGlnLeuLeuLeu6065AAAGCCACGAAGGCTGATGACAAGGGAAGCAACAAA290LysAlaThrLysAlaAspAspLysGlySerAsnLys7075GGTTTTGAAGCCACATACCGTAAAGAAACCACTTCT326GlyPheGluAlaThrTyrArgLysGluThrThrSer808590TTCCACTTGGAGAAAGGCTCAGTTCAAGTGTCAGAC362PheHisLeuGluLysGlySerValGlnValSerAsp95100TCAGCGGTGTACTTCTGTGCT383SerAlaValTyrPheCysAla105110(2) INFORMATION FOR SEQ ID NO: 11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 364(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: IGR a 13(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE V .alpha. 16(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:AATCCCGCCCGCCGTGAGCTTAGCTGGAGCCATGGCCTCT40MetAlaSer1GCACCCATCTCGATGCTTGCGATGCTCTTCACATTG76AlaProIleSerMetLeuAlaMetLeuPheThrLeu51015AGTGGGCTGAGAGCTCAGTCAGTGGCTCAGCCGGAA112SerGlyLeuArgAlaGlnSerValAlaGlnProGlu2025GATCAGGTCAACGTTGCTGAAGGGAATCCTCTGACT148AspGlnValAsnValAlaGluGlyAsnProLeuThr3035GTGAAATGCACCTATTCAGTCTCTGGAAACCCTTAT184ValLysCysThrTyrSerValSerGlyAsnProTyr404550CTTTTTTGGTATGTTCAATACCCCAACCGAGGCCTC220LeuPheTrpTyrValGlnTyrProAsnArgGlyLeu5560CAGTTCCTTCTGAAATACATCACAGGGGATAACCTG256GlnPheLeuLeuLysTyrIleThrGlyAspAsnLeu657075GTTAAAGGCAGCTATGGCTTTGAAGCTGAATTTAAC292ValLysGlySerTyrGlyPheGluAlaGluPheAsn8085AAGAGCCAAACCTCCTTCCACCTGAAGAAACCATCT328LysSerGlnThrSerPheHisLeuLysLysProSer9095GCCCTTGTGAGCGACTCCGCTTTGTACTTCTGTGCT364AlaLeuValSerAspSerAlaLeuTyrPheCysAla100105110(2) INFORMATION FOR SEQ ID NO: 12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 263(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 01(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:CCTTCAAGGAAAATTAAGGCAAATAGAATTGGGCTGGGGA40GTTGCTACTTATTAGTATTCCTCCCACGTTCTAACCTAAT80TATAAGGAGGTTGTTTTGGCCATGGGCAGTCATCTCAGGT120TTTGTTTTCCTGCTTTCCTCCCTAACCTCCACCTGTCTTC160CTAGAGGCCTGAGTCAAGGTTATTGCAATAGCACTAAAGA200CTGTGTAACACCAATGCAGGCAAATCAACCTTT233AsnThrAsnAlaGlyLysSerThrPhe15GGGGATGGGACTACGCTCACTGTGAAGCCA263GlyAspGlyThrThrLeuThrValLysPro1015(2) INFORMATION FOR SEQ ID NO: 13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 277(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 02(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:AAGGACACAGACTGCCTGCATGAAGGCTGGAGCTGGGCCC40AGGATGAGGAAAGGCCTCAGGAAGGAAGGGCTGACACGAA80ATAAGGAATACCATGGCATTCATGAGATGTGCGTCTGAAT120CCTCTCTCTTGCCTGAGAAGCTTTAGCTTCCACCTTGAGA160CACAAAACATGTGGTTATGAAGAGATGACAAGGTTTTTGT200AAAAGAATGAGCCATTGTGGATAGGCTTTGGGAAT235IleGlyPheGlyAsn15GTGCTGCATTGCGGGTCCGGCACTCAAGTGATTGTT271ValLeuHisCysGlySerGlyThrGlnValIleVal1015TTACCA277LeuPro(2) INFORMATION FOR SEQ ID NO: 14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 60(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 04(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:TAGATACTGGAGGCTTCAAAACTATCTTTGGAGCA35AspThrGlyGlyPheLysThrIlePheGlyAla1510GGAACAAGACTATTTGTTAAAGCAA60GlyThrArgLeuPheValLysAla15(2) INFORMATION FOR SEQ ID NO: 15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 59(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 05(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J .alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:CCTAACTGGGGCAAACAACGTCTTCTTTGGGACT34LeuThrGlyAlaAsnAsnValPhePheGlyThr1510GGAACGAGACTCACCGTTCTTCCCT59GlyThrArgLeuThrValLeuPro15(2) INFORMATION FOR SEQ ID NO: 16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 60(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 06(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:ATGGAGGAAGCCAAGGAAATCTCATCTTTGGAAAA35GlyGlySerGlnGlyAsnLeuIlePheGlyLys1510GGCACTAAACTCTCTGTTAAACCAA60GlyThrLysLeuSerValLysPro15(2) INFORMATION FOR SEQ ID NO: 17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 56(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 07(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:GGAGCCAATAGTAAGCTGACATTTGGAAAAGGAATA36GlyAlaAsnSerLysLeuThrPheGlyLysGlyIle1510ACTCTGAGTGTTAGACCAGA56ThrLeuSerValArgPro15(2) INFORMATION FOR SEQ ID NO: 18:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 57(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 08(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:CTGGTGGCTACAATAAGCTGATTTTTGGAGCAGGG35GlyGlyTyrAsnLysLeuIlePheGlyAlaGly1510ACCAGGCTGGCTGTACACCCAT57ThrArgLeuAlaValHisPro15(2) INFORMATION FOR SEQ ID NO: 19:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 50(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: DOUBLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: cDNA to mRNA(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY: Ja 09(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: SEQUENCE J.alpha.60(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:TGGAAACAAGCTGGTCTTTGGCGCAGGAACCATT34GlyAsnLysLeuValPheGlyAlaGlyThrIle1510CTGAGAGTCAAGTCCT50LeuArgValLysSer15(2) INFORMATION FOR SEQ ID NO: 20:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: A(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:GTTGCTCCAGGCCACAGCACTG22(2) INFORMATION FOR SEQ ID NO: 21:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: POLY C(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:GCATGCGCGCGGCCGCGGAGGCCCCCCCCCCCCCC35(2) INFORMATION FOR SEQ ID NO: 22:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: B(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:GTCCATAGACCTCATGTCCAGCACAG26(2) INFORMATION FOR SEQ ID NO: 23:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: C(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:ATACACATCAGAATTCTTACTTTG24(2) INFORMATION FOR SEQ ID NO: 24:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: D(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:GTCACTGGATTTAGAGTCT19(2) INFORMATION FOR SEQ ID NO: 25:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.1, CLONE AB22,POSITION 235(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:GGCATTAACGGTTTTGAGGCTGGA24(2) INFORMATION FOR SEQ ID NO: 26:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.2, CLONE IGRa09,POSITION 93*(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:CAGTGTTCCAGAGGGAGCCATTGC24(2) INFORMATION FOR SEQ ID NO: 27:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V .alpha.3, CLONE HAP05,POSITION 297(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:CCGGGCAGCAGACACTGCTTCTTA24(2) INFORMATION FOR SEQ ID NO: 28:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V .alpha.4, CLONE HAP08,POSITION 153(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:TTGGTATCGACAGCTTCCCTCCCA24(2) INFORMATION FOR SEQ ID NO: 29:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.5, CLONE IGRa10,POSITION 113(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:CGGCCACCCTGACCTGCAACTATA24(2) INFORMATION FOR SEQ ID NO: 30:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.6, CLONE HAP01,POSITION 287(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:TCCGCCAACCTTGTCATCTCCGCT24(2) INFORMATION FOR SEQ ID NO: 31:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.7, CLONE IGRall,POSITION 159(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:GCAACATGCTGGCGGAGCACCCAC24(2) INFORMATION FOR SEQ ID NO: 32:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.8, CLONE HAP41,POSITION 204(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:CATTCGTTCAAATGTGGGCAAAAG24(2) INFORMATION FOR SEQ ID NO: 33:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.9, CLONE HAVP36,POSITION 168(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:CCAGTACTCCAGACAACGCCTGCA24(2) INFORMATION FOR SEQ ID NO: 34:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.10, CLONE HAP58,POSITION 282(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:CACTGCGGCCCAGCCTGGTGATAC24(2) INFORMATION FOR SEQ ID NO: 35:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.11, CLONE AB19,POSITION 254*(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:CGCTGCTCATCCTCCAGGTGCGGG24(2) INFORMATION FOR SEQ ID NO: 36:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.12, CLONEV12MA483, POSITION 213(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:TCGTCGGAACTCTTTTGATGAGCA24(2) INFORMATION FOR SEQ ID NO: 37:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.13, CLONEHAVT15, POSITION 152*(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:TTCATCAAAACCCTTGGGGACAGC24(2) INFORMATION FOR SEQ ID NO: 38:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.14, CLONEHAVT20, POSITION 181(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:CCCAGCAGGCAGATGATTCTCGTT24(2) INFORMATION FOR SEQ ID NO: 39:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.15, CLONEHAVT31, POSITION 278(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:TTGCAGACACCGAGACTGGGGACT24(2) INFORMATION FOR SEQ ID NO: 40:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.16, CLONEIGRa13, POSITION 89(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:TCAACGTTGCTGAAGGGAATCCTC24(2) INFORMATION FOR SEQ ID NO: 41:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.17, CLONE AB11,POSITION 204(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:TGGGAAAGGCCGTGCATTATTGAT24(2) INFORMATION FOR SEQ ID NO: 42:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.18, CLONE AB21,POSITION 114(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:CAGCACCAATTTCACCTGCAGCTT24(2) INFORMATION FOR SEQ ID NO: 43:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.19, CLONE AC24,POSITION 162(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:ACACTGGCTGCAACAGCATCCAGG24(2) INFORMATION FOR SEQ ID NO: 44:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.20, CLONE AE212,POSITION 232(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:TCCCTGTTTATCCCTGCCGACAGA24(2) INFORMATION FOR SEQ ID NO: 45:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.21, CLONE AF211,POSITION 92(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:AGCAAAATTCACCATCCCTGAGCG24(2) INFORMATION FOR SEQ ID NO: 46:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.22, CLONEIGRa12, POSITION 197(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:CCTGAAAGCCACGAAGGCTGATGA24(2) INFORMATION FOR SEQ ID NO: 47:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w23, CLONEIGRa01, POSITION 246(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:TGCCTCGCTGGATAAATCATCAGG24(2) INFORMATION FOR SEQ ID NO: 48:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w24, CLONEIGRa02, POSITION 259(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:CTGGATGCAGACACAAAGCAGAGC24(2) INFORMATION FOR SEQ ID NO: 49:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w25, CLONEIGRA03, POSITION 148(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:TGGCTACGGTACAAGCCGGACCCT24(2) INFORMATION FOR SEQ ID NO: 50:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w26, CLONEIGRa04, POSITION 299(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:AGCGCAGCCATGCAGGCATGTACC24(2) INFORMATION FOR SEQ ID NO: 51:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w27, CLONEIGRa05, POSITION 268*(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:AAGCCCGTCTCAGCACCCTCCACA24(2) INFORMATION FOR SEQ ID NO: 52:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w28, CLONEIGRa06, POSITION 95(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:TGGTTGTGCACGAGCGAGACACTG24(2) INFORMATION FOR SEQ ID NO: 53:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(B) STRAIN:(C) INDIVIDUAL ISOLATE:(D) DEVELOPMENTAL STAGE:(E) HAPLOTYPE:(F) TISSUE TYPE:(G) CELL TYPE:(H) CELL LINE: HUMAN T LYMPHOCYTE(I) ORGANELLE:(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE V.alpha.w29, CLONEIGRa07, POSITION 210(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:GAAGGGTGGAGAACAGATGCGTCG24(2) INFORMATION FOR SEQ ID NO: 54:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE C.+-.A, POSITION 129(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:ATACACATCAGAATTCTTACTTTG24(2) INFORMATION FOR SEQ ID NO: 55:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE C.+-.B, POSITION 201(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:GTTGCTCCAGGCCGCGGCACTGTT24(2) INFORMATION FOR SEQ ID NO: 56:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE C.+-.C, POSITION 57(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:GTCACTGGATTTAGAGTCT19(2) INFORMATION FOR SEQ ID NO: 57:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE Act 1, CLONE A-actin, POSITION 1161(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:ATTTGCGGTGGACGATGGAGGGGC24(2) INFORMATION FOR SEQ ID NO: 58:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE Act 2, CLONE A-ACTIN, POSITION 261(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:GGCATCGTCACCAACTGGGACGAC24(2) INFORMATION FOR SEQ ID NO: 59:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE Act 3, CLONE A-ACTIN, POSITION 642(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:ACCACCACGGCGGAGCGGG19(2) INFORMATION FOR SEQ ID NO: 60:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE CAF, POSITION 135(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:CGGGCTGCTCCTTGAGGGGCTGCG24(2) INFORMATION FOR SEQ ID NO: 61:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE CAK, POSITION 20(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:CCCACCCGAGGTCGCTGTG19(2) INFORMATION FOR SEQ ID NO: 62:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: NUCLEOTIDE(C) STRANDEDNESS: SINGLE(D) TOPOLOGY: LINEAR(ii) MOLECULE TYPE: OLIGONUCLEOTIDE(ix) FEATURE:(A) NAME/KEY:(B) LOCATION:(C) IDENTIFICATION METHOD:(D) OTHER INFORMATION: TYPE CAC, POSITION 58(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:TCTGCTTCTGATGGCTCAA19__________________________________________________________________________

Number	Date	Country	Kind
91 01487	Feb 1991	FRX
91 04527	Apr 1991	FRX

Nucleotide sequences for .alpha. chain variable regions in human lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (2)

PRIOR APPLICATION

Foreign Referenced Citations (1)

Non-Patent Literature Citations (3)

Divisions (1)

Continuations (1)

Entry
Klein et. al. P.N.A.S. USA 84:6884-6888 (Oct. 1987).
Roman-Roman et. al. Eur. J. Immunol 21:927-933 (Apr. 1991).
Sottini et. al. Eur. J. Immunol 21:461-466 (Feb. 1991).